Browse our wide selection of products for your research needs
We can offer a discount on bulk orders.
Please contact our sales team for further inquiry.
| Product Name | MAN-LNP@Citraconic acid, mannose-modified liposome loaded with citraconic acid |
| Catalog Number | R-dz-8800 |
| Alias | Lucose-modified lipid nanoparticles@citraconic acid |
| Appearance | Dispersion |
| Molecular Formula | N/A |
| Solubility | Ethanol, dimethyl sulfoxide |
| Storage | 2-8°C, protected from light |
| Purity | 95%+ |
| Shelf Life | 1 year |
| Shipping Condition | low temperature transport |
| Application | gene delivery |
| Specification | 10mg:Inquiry 20mg:Inquiry 50mg:Inquiry |
| Description | MAN-LNP@Citraconic acid is a new composite system that combines mannose-modified lipid nanoparticles with citraconic acid. Lipid nanoparticles (LNP) have good biocompatibility and drug-loading capacity, and can effectively package nucleic acids, small molecule drugs, etc. The modification of mannose (MAN) enables the system to specifically recognize the mannose receptor on the cell surface, thereby achieving targeted delivery and improving the enrichment efficiency of the drug in the target tissue or target cells. The introduction of citraconic acid gives the system acid-responsive characteristics. Citraconic acid is stable in neutral environments, but under acidic conditions such as tumor microenvironment, the chemical bonds modified by citraconic acid will break, prompting rapid release of the drug and achieving controlled release of the drug. This structural design enables it to show application potential in biomedical fields such as tumor targeted treatment and gene delivery. |